Search - tctmd.com

Displaying 61 - 80 of 146

Sort: Relevancy | Date

News Conference News EuroPCR 2024

ShortCut Leaflet Splitter Proves Safe, May Streamline Valve-in-Valve TAVI

Shelley Wood

May 16, 2024

Presentation EuroPCR 2024

First report of an IDE pivotal study of a dedicated splitting device during TAVR

Presenter: Danny Dvir

May 15, 2024

Presentation EuroPCR 2024

QFR for the revascularization of non-culprit lesions of older patients with myocardial infarction

Presenter: Andrea Erriquez

May 14, 2024

Presentation EuroPCR 2024

Prognostic value of MRR in STEMI: a pooled analysis of individual patient data

Presenter: Mohamed El Farissi

May 14, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Conference News SCAI 2024

AI Picks Up on Info Operators Miss on Angiograms: AI-ENCODE

L.A. McKeown

May 03, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Features

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Caitlin E. Cox

May 02, 2024

News Daily News

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Michael O'Riordan

May 02, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Caitlin E. Cox

April 12, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Presentation ACC 2024

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

Presenter: Gervasio A. Lamas

April 07, 2024

Presentation ACC 2024

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Presenter: Gregg W Stone

April 07, 2024

Presentation ACC 2024

Percutaneous Transvalvular Micro axial Flow Pump in Infarct Related Cardiogenic Shock

Presenter: Jacob Eifer Møller

April 07, 2024

News Conference News ACC 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

Caitlin E. Cox

April 07, 2024

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

Advertisement

ShortCut Leaflet Splitter Proves Safe, May Streamline Valve-in-Valve TAVI

First report of an IDE pivotal study of a dedicated splitting device during TAVR

QFR for the revascularization of non-culprit lesions of older patients with myocardial infarction

Prognostic value of MRR in STEMI: a pooled analysis of individual patient data

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

AI Picks Up on Info Operators Miss on Angiograms: AI-ENCODE

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Percutaneous Transvalvular Micro axial Flow Pump in Infarct Related Cardiogenic Shock

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content